Old Web
English
Sign In
Acemap
>
Paper
>
56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
2016
Scott N. Gettinger
Lyudmila Bazhenova
Ravi Salgia
Corey J. Langer
Kathryn A. Gold
Rafael Rosell
Alice T. Shaw
Glen J. Weiss
David J. Dorer
Victor M. Rivera
D. Kerstein
D.R. Camidge
Keywords:
Brigatinib
Pathology
Medicine
Oncology
Radiology
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI
[]